Christopher Cannon, MD, Professor of Medicine at Harvard Medical School, discusses the recent topline results from REDUCE-IT, the Vascepa cardiovascular (CV) outcomes trial. The REDUCE-IT trial was a global study study of 8,179 statin-treated adults with elevated CV risk. The trial met its primary endpoint, demonstrating a 25% relative risk reduction in major adverse CV events (MACE) in the intent-to-treat patient population with use of Vascepa 4 g/day versus placebo. The full results will be presented at the American Heart Association Scientific Sessions

Check out Dr. Cannon as he discusses Antithrombotic Therapy in AFib Patients Undergoing PCI

For more info on REDUCE-IT Click Here